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Inhibition of Glycolysis Reduces
Disease Severity in an Autoimmune
Model of Rheumatoid Arthritis
Georges Abboud 1†, Seung-Chul Choi 1†, Nathalie Kanda 1, Leilani Zeumer-Spataro 1,
Derry C. Roopenian 2 and Laurence Morel 1*
1 Immunology, and Laboratory Medicine, Department of Pathology, University of Florida, Gainesville, FL, United States, 2 The
Jackson Laboratory, Bar Harbor, ME, United States
The K/BxNmouse is a spontaneous model of arthritis driven by T cell receptor transgenic
CD4+ T cells from the KRN strain that are activated by glucose-6-phosphate isomerase
(GPI) peptides presented by the H-2g7 allele from the NOD strain. It is a model of
autoimmune seropositive arthritis because the production of anti-GPI IgG is necessary
and sufficient for joint pathology. The production of high levels of anti-GPI IgG requires
on the expansion of CD4+ follicular helper T (Tfh) cells. The metabolic requirements of
this expansion have never been characterized. Based on the therapeutic effects of the
combination of metformin and 2-deoxyglucose (2DG) in lupus models that normalized
the expansion of effector CD4+ T cells. We showed that the CD4+ T cells and to a
lesser extent, the B cells from K/BxN mice are more metabolically active than the KRN
controls. Accordingly, preventive inhibition of glycolysis with 2DG significantly reduced
joint inflammation and the activation of both adaptive and innate immune cells, as well
as the production of pathogenic autoantibodies. However, contrary to the lupus-prone
mice, the addition of metformin had little beneficial effect, suggesting that glycolysis is
the major driver of immune activation in this model. We propose that K/BxN mice are
another model in which autoreactive Tfh cells are highly glycolytic and that their function
can be limited by inhibiting glucose metabolism.
Keywords: arthritis, mouse, follicular helper T cells, glycolysis, metabolism
INTRODUCTION
The concept that cellular metabolism controls the functions of immune cells has greatly evolved in
the past few years, with T cells leading the way over other immune cell types (1, 2). Quiescent T cells
produce ATP by oxidizing glucose, fatty acids or glutamine. TCR/CD28 stimulation upregulates
glucose uptake to generate ATP as well as biosynthesis intermediates through the reduction of
pyruvate into lactate in a process known as aerobic glycolysis. A number of metabolic inhibitors
block key nodes of T cell metabolism. 2-deoxyglusose (2DG) inhibits glucose metabolism at its first
enzymatic steps. Metformin reduces mitochondrial respiration in activated T cells (3), which is
consistent with its inhibition of the electron transport chain complex 1 (4). Based on the drastic
differences in metabolic requirements and the critical role of effector T cells in autoimmune
diseases, T cell metabolism has been proposed as a target for immunotherapy (5, 6). We and
others have shown the existence of multiple immune metabolism defects in lupus patients and
mouse models of the disease (7). We have also shown that the combination of 2DG and metformin
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normalized the metabolism of lupus CD4+ T cells and reverse
disease in multiple mouse models (3, 8).
Activated CD4+ T cells in rheumatoid arthritis (RA) patients
shunt glucose flux to the pentose phosphate pathway leading
to a hyper-reduced state (9), due in part in a deficiency
in phosphofructokinase PFKFB3 (10). Treatments with drugs
increasing mitochondrial oxidation (9) or preventing FA
synthesis (11) normalized the metabolism of these T cells, and
decreased their infiltration into synovial tissue implanted in
humanized mice. In the zymosan-induced model of arthritis,
treatment with fructose 1,6-bisphosphate (FBP), the product
of PFKFB3, attenuated disease severity (12). Lymphocytes
infiltrating the joints of RA patients express a high levels of
hexokinase HK2, indicating that they are also highly glycolytic,
which is consistent with their activation status (13). Inhibition of
glycolysis with bromo-pyruvate greatly reduced disease severity
in the SGK mouse, another zymosan-induced model of arthritis
driven by Th17 cell expansion (13), which is consistent with Th17
cell dependence on glycolysis (14). Fibroblast-like synoviocytes
(FLS) are also highly glycolytic in the inflamed joints of RA
patients and in the murine K/BxN (KBN) serum transfer
model (15). In this model of immune complex induced joint
inflammation, bromo-pyruvate prevented and reversed disease,
suggesting that FLS are the primary target (15). Overall, there is
evidence of metabolic disturbances in the immune and joint cells
associated with RA, with glucose metabolism playing a key role.
The KBN mouse is a spontaneous model of arthritis driven
by T cell receptor transgenic CD4+ T cells from the KRN
strain that are activated by glucose-6-phosphate isomerase
(GPI) peptides presented by the H-2g7 allele from the NOD
strain (16). It is a model of autoimmune arthritis because the
production of anti-GPI IgG is necessary and sufficient for joint
pathology. Indeed KBN serum induces disease by activating
inflammatory innate cells, especially neutrophils, in the effector
phase of the disease leading to joint damage (17). GPI is highly
expressed in the arthritic joint (18), and the formation of
anti-GPI immune complexes triggers an inflammatory cascade
leading to tissue damage. Based on therapeutic effects of the
combination of metformin and 2DG in lupus mouse models that
normalized the expansion of effector CD4+ T cells (3, 8), we
hypothesized that these metabolic inhibitors would also have a
beneficial effect in autoimmune arthritis. We showed that the
CD4+ T cells and to a lesser extent, the B cells from KBN
mice are more metabolically active than the KRN controls.
Accordingly, inhibition of glycolysis with 2DG significantly
reduced joint inflammation and the activation of both adaptive
and innate immune cells, as well as the production of pathogenic
autoantibodies. However, contrary to the lupus-prone mice, the
Abbreviations: 2DG, 2-deoxyglusose; RA, rheumatoid arthritis; KBN,
K/BxN; FLS, Fibroblast-like synoviocytes; Met, metformin; GPI, glucose-6-
phosphate isomerase; Tg, transgenic; B6, C57BL/6J mice; ECAR, Extracellular
acidification rate; OCR, Oxygen consumption rate; SrC, spare respiratory
capacity; DC, dendritic cell; pDC, plasmacytoid dendritic cell; Tfh,
CD44+CD279+CXCR5+Bcl6+Foxp3−CD4+ follicular helper T cells; Treg,
CD25+Foxp3+CD4+ regulatory T cells; TEM, CD44+CD62L− CD4+ effector
memory T cells.
addition of metformin had little beneficial effect, suggesting that
glycolysis is the major driver of immune activation in this model.
MATERIALS AND METHODS
Mice and Disease Assessment
KBN mice were F1 hybrids between TCR transgenic (Tg) KRN
females and NOD males, both obtained from The Jackson
Laboratory. The KRN strain was maintained by out-crossing
to C57BL/6 (B6), and the presence of the Tg was detected
by PCR (19). B6 mice were also used as controls in some
experiments. Both males and females were used. Treatment
with 2DG (6 mg/ml) with or without metformin (3 mg/ml)
was administered in drinking water as previously described (3),
starting between 30 and 35 days of age for the entire duration of
the experiment. Littermate controls received plain water. Serum
transfers were conducted as described (19). Briefly, 300 ul of
pooled serum collected from metformin + 2DG (Met+2DG),
2DG-treated or control mice was injected at day 1 and 3 into
5–6 month old KRN males. Joint thickness was measured on
all 4 limbs 3 times a week with a caliper and disease severity
was assessed on a semi-quantitative scale as previously described
(19). Results are reported as the sum measurements or scores
for all 4 limbs. Three cohorts of 2DG treatment and controls
were performed, as well as three additional cohorts of metformin
+ 2DG (Met+2DG), 2DG alone, and controls. Two cohorts of
serum transfers were performed with sera from 2DG-treated and
control mice, as well as with sera from Met+2DG, 2DG-treated,
or control mice. Results were presented on pooling cohorts.
The levels of serum anti-GPI IgG were measured by ELISA
with in plates coated with 5µg/ml recombinant GPI (19) with
serum samples diluted 1:1000. This study was carried out in
strict accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the animal Welfare
Act and the National Institutes of Health guidelines for the
care and use of animals in the biomedical research. All animal
protocols were approved by the Institutional Animal Care and
Use Committee (IACUC) of the University of Florida, Gainesville
(OLAW Assurance # A3377-01).
Flow Cytometry
Single-cell suspensions were prepared from spleens and brachial
lymph nodes using standard procedures. After red blood cell
lysis, cells were blocked with anti-CD16/32 Ab (2.4G2), and
stained in FACS staining buffer (2.5% FBS, 0.05% sodium
azide in PBS). Fluorochrome-conjugated Abs used were to
B220 (RA3-6B2), BCL6 (K112-91), CD3 (145-2C11), CD4
(RAM4-5), CD8 (53-6.7), CD11b (M1/70), CD11c (HL3), CD25
(PC61.5), CD44 (IM7), CD62L (MEL-14), CD69 (H1.2F3),
CD95 (Jo2), CD98 (RL388), CD138 (281-2), CD162 (PSLG-1,
2PH1), CD279 (PD-1, RMP1-30), Foxp3 (FJK-16s), I-A/I-E
(MHC-II, M5/114.15.2), IL-17A (TC11-18h10.1), Ly6C (HK1.4)
and Ly6G (1A8), Ly-77 (GL7), pAKT-s473(SDRNR), pE4-BP
(236B4), pS6 (D57.2.2E), and PDCA-1 (129C1), purchased
from BD Biosciences, Thermo Fisher, BioLegend, or Cell
Signaling Technology. Monocyte/macrophages were gated as
CD3– CD11b+Ly6Chi while neutrophils were CD3– CD11bhi
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Ly6G+. Follicular helper T cells were stained as previously
described (3) in a three-step process using purified CXCR5 (2G8)
followed by biotinylated anti-rat IgG (Jackson ImmunoResearch
Laboratory) then PerCP-labeled streptavidin in FACS staining
buffer on ice. For the intracellular staining, cells were fixed
and permeabilized with FOXP3 stating buffer (Thermo Fisher)
according to the manufacturer’s protocol.
Metabolic Measurements
Single splenocyte suspensions were enriched for total CD4+
T cells or B cells by negative selection with magnetic beads
(Miltenyi). Glycolysis recorded as Extracellular Acidification
Rate (ECAR) and Oxygen Consumption Rate (OCR) were
measured using a XF96 Extracellular Flux Analyzer (Agilent
Seahorse) in a standard mitochondrial stress assay with non-
buffered RPMI medium (Sigma) supplemented with 2.5 uM
dextrose, 2mM glutamine and 1 uM Sodium Pyruvate. Samples
were assayed at least in triplicates for 3 successive 8min
time intervals between inhibitor injections. Baseline ECAR
and OCR values were averaged between replicates for these
3 time points. Mitochondrial spare respiratory capacity (SRC)
was defined as the OCR difference between baseline and
maximum respiration after injection of Carbonyl cyanide
4-(trifluoromethoxy) phenylhydrazone (FCCP).
STATISTICAL ANALYSIS
Analyses were performed using GraphPad Prism 6.0. Unless
indicated, graphs show means and standard errors of the mean.
Comparisons were performed using two-tailed unpaired student
t-tests and 2-way ANOVA. Statistical significance was defined as
P < 0.05.
RESULTS
KBN Lymphocytes Have a High Cellular
Metabolism
We compared the basis metabolic parameters of total B cells and
CD4+ T cells between KBN and KRN mice, which share the
same Tg TCR repertoire, at 6 weeks of age, which is an early
disease stage for KBN mice. A B6 mouse was used as control.
KBN B cells showed a similar OCR profile as KRN, but glycolysis
was globally higher in KBN than KRN B cells, especially when
mitochondrial ATP production was inhibited after oligomycin
and FCCP treatment (Figure 1A). KBN CD4+ T cells showed a
higher basal OCR and a higher SRC, as well as a higher glycolysis,
especially, as for B cells, whenmitochondrial ATP productionwas
inhibited (Figures 1B,C). Consistent with a higher metabolism,
KBN CD4+ T cells and B cells also showed a higher mTORC1
activation as measured by pS6, pE4-BP and CD98 expression,
as compared to KRN (Figure 1D). Overall, these results show
that consistent with their autoantibody production for B cells
(20) and their enhance effector functions for CD4+ T cells
(1), KBN lymphocytes are more metabolically active than KRN
controls.
Inhibition of Glucose Metabolism Inhibits
the Development of Joint Inflammation
We first addressed whether treatment with 2DG initiated
prior to disease onset. Robust joint swelling developed in
KBN females with earlier onset than males (Figure 2A).
Consequently, the results are reported separately for males
and females. Treatment with 2DG starting at 5 weeks of age
when joint inflammation was minimal significantly decreased
swelling (Figure 2A), as well as clinical scores (Figure 2B).
There was also a significant effect of the treatment as
measured by the individual changes in joint thickness after
about 2 months of continued treatment (Figure 2C). Thus,
2DG inhibited but did not fully abrogate the development
of the clinical features of KBN arthritis. We then addressed
whether 2DG treatment affected joint inflammation in mice
in which treatment was initiated when disease was established.
2DG therapy initiated 51 days (females) and 61 days caused
partial reduction of joint inflammation (Figures 2D,E). However,
levels of serum anti-GPI IgG were not decreased in the
majority of mice receiving the preventive 2DG treatment
(Figure 2F) but sera from 2DG-treated mice induced less
inflammation as compared to control sera when transferred into
KRN mice (Figure 2G). This indicates that glucose inhibition
induced qualitative differences in anti-GPI IgG arthrogenic
activity.
Inhibition of Glucose Metabolism Affects
Multiple Cell Populations Involved in KBN
Arthritis
The preventive 2DG treatment reduced lymphoid expansion
in the spleen and the number of splenocytes correlated
with disease severity (Figure 3A). The total percentage of B
cells and CD4+ T cells was unchanged (data not shown).
2DG reduced the frequency of germinal center (GC) B
cells, which also correlated with disease activity (Figure 3B),
and the frequency of splenic plasma cells (Figure 3C). The
lack of correlation between this latter variable and joint
swelling may indicate that the majority of plasma cells or
plasmablasts have moved to the bone marrow. The number
of cells (Figure 3D) and the frequency of GC B cells
(Figure 3E) were also reduced in the joint draining lymph node
(JDLN).
The frequencies of Tfh cells (Figure 4A), activated
CD69+CD4+ T cells (Figure 4B) and IL-17A producing
CD4+ T cells (Figure 4C) were greatly reduced by the 2DG
treatment, all of which correlated with disease severity. 2DG
also decreased the frequency of Foxp3+CD25+CD4+ regulatory
T cells (Treg), a subset that has not reported to be involved in
this model, and the frequency of Tregs was also correlated with
disease severity (Figure 4D). As we have previously reported
in lupus mice (8), 2DG alone did not reduced the frequency of
CD44+CD62−CD4+ effector memory T cells (TEM), and the
frequency of these cells did not correlate with joint inflammation
(Figure 4E).
Finally, class-switched autoantibodies resulting from the
expansion of GC B cells and Tfh cells require myeloid cells
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FIGURE 1 | KBN lymphocytes have a high metabolism. Mitochondrial stress test in B cells (A) and CD4+ T cells (B) purified from 6 week old KRN and KBN females
(N = 3) with one B6 female shown as control. ECAR plots were compared between KRN and KBN mice by 2-way ANOVA. (C). Basal OCR and SRC as well as
maximum ECAR in CD4+ T cells and B cells calculated from data shown in (A,B). (D). pS6, pE4-BP, CD98 and pAKT in CD4+ T cells and B cells (N = 5). t-tests
were used in C and D. *p < 0.05; **p < 0.01; ***p < 0.001.
to induce inflammation in the joint (21). 2DG treatment
reduced the number of monocytes (Figure 5A) and neutrophils
(Figure 5B) in the JDLN. A positive correlation was observed
between the numbers of these myeloid cells and joint
inflammation (Figure 5). Overall, the disease attenuation that
occurred in KBN mice treated with 2DG correlated with
a reduction of multiple immune cells whose expansion has
been reported to contribute to autoimmune pathogenesis in
this model: GC B cells, Tfh and Th17 CD4+ T cells and
myeloid cells.
The Addition of Metformin Does Not
Improve the Effect of 2DG Treatment
Since the 2DG treatment did not completely prevent disease in
KBN mice (Figure 2), we tested whether acted synergistically
protection as we have documented in lupus-prone mice (3).
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FIGURE 2 | Glycolysis inhibition reduced joint inflammation in KBN mice. Time course of joint thickness (A) and clinical scores (B) in mice treated or not with 2DG
(female controls N = 11; female 2DG N = 12; male controls N = 7; male 2DG N = 9). (C). Percent change in joint thickness between d 35 and d 61 in these mice
(t-tests). (D). Time course of joint thickness in mice in which treatment with 2DG started after severe joint inflammation was established, at 51 d old for females and 61
d old for males (as indicated by arrows). (E). Changes in joint thickness after 2DG treatment shown in (D) in individual mice (initial and terminal measurements, paired
t-tests). (F). Serum anti-GPI IgG in mice treated preventively or not with 2DG as shown in (A,B) (geometric means ± 95% confidence intervals). (G). Joint thickness in
KRN mice after transfer of serum from KBN mice treated with 2DG or controls (N = 6 each). An uninjected KRN mouse is included as control. Plots in (A,B,G) were
compared by 2-way ANOVA. *p < 0.05; **p < 0.01; ***p < 0.001.
FIGURE 3 | Glycolysis inhibition reduced lymphoid expansion as well as GC B cells and plasma cell differentiation. Mice treated with 2DG showed a reduced number
of splenocytes (A) and frequency of GL7+CD95+ GC B cells (B), both of which were correlated with disease severity, as well as a reduction of the frequency of
CD138+B220lo/neg plasma cells, which was not correlated with disease activity (C). 2DG also reduced the number of cells (D) and the frequency of GC B cells (E) in
the JDLN. Mean values between the treated and control mice were evaluated with t-tests. *p < 0.05; **p < 0.01; ***p < 0.001. Correlations between joint thickness
and immune variables were computed by pooling the 4 groups of mice and evaluated with a Pearson test as indicated for each graph.
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FIGURE 4 | Glycolysis inhibition reduced Tfh and Th17 cell expansion. Mice treated with 2DG showed a reduced frequency of Tfh (A), CD4+ T cells expressing the
activation marker CD69 (B), Th17 (C) and Treg (D) cells, all of which were correlated with disease severity. The frequency of TEM cells was not decreased by the 2DG
treatment and TEM frequency was no correlated to disease severity (E). Mean values between 2DG-treated and control mice were evaluated with t-tests. Correlations
were evaluated with the Pearson test. **p < 0.01; ***p < 0.001.
FIGURE 5 | Glycolysis inhibition reduced the frequency of neutrophils and monocytes in the JDLN and altered their activation. The frequency of monocytes (A) and
neutrophils (B) was reduced by 2DG treatment, and the number of these cells in the joint draining lymph node correlated with disease severity. Mean values between
the treated and control mice were evaluated with t-tests. Correlations were evaluated with the Pearson test. **p < 0.01; ***p < 0.001.
The combined treatment of metformin and 2DG (Met+2DG)
did not significantly change clinical outcomes as compared
to mice that were treated with 2DG alone (Figure 6A).
However, sera obtained from the Met+2DG-treated mice
induced significantly more joint inflammation than that
of 2DG-treated mice when transferred into KRN mice
(Figure 6B).
To understand the basis for these differences, we compared
the effect of the two treatments on the metabolic parameters
of CD4+ T cells of these mice. 2DG significantly decreased
both respiration (Figure 6C) and glycolysis (Figure 6D), as
measured at either basal or maximal levels, but the addition of
metformin did not improve this metabolic inhibition. Further,
the addition of metformin did not improve the inhibitory effect
of 2DG on the expansion of Tfh cells, CD69+CD4+ T cells,
GC B cells and plasma cells (Figures 7A,B,E,F). Interestingly,
the addition of metformin eliminated the inhibitory effect of
2DG on Th17 and Treg cell expansion (Figures 7C,D). On the
contrary, Met+2DG decreased the frequency of Tem while the
effect of 2DG alone was not significant (Figure 7G), confirming
the results obtained with the previous cohort (Figure 4E).
Finally, the combination of Met+2DG had a similar effect
on monocytes and CD11b+ myeloid dendritic cells than 2DG
alone (Figures 7H,K). However, the addition of metformin
negated the beneficial effect of 2DG on neutrophils, pDCs and
CD11bnegative DCs (Figures 7I,J,L). Overall these results suggest
that glycolysis is the driving metabolic process in the KBN
model.
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FIGURE 6 | Metformin does not improve the protective effect of 2DG: (A). Time course of joint thickness in KBN mice treated with Met+2DG (8 females and 7 males),
2DG (9 females and 6 males) or untreated controls (5 females and 2 males). The 2DG treated and control mice were contemporaneous to the Met+2DG treated mice,
and were a different cohort from the mice presented in Figure 2. The results were pooled between males and females. Treatments were compared to controls by a
2-way ANOVA. (B). Joint thickness in KRN mice after transfer of serum from KBN mice treated with Met+2DG, 2DG, or controls (N = 8 recipient each). Mean terminal
values between treated and control mice were evaluated with t-tests. For both A and B, results were expressed as percentage change from the first day of treatment
or serum transfer. OCR (C) and ECAR (D) from a mitochondrial stress test in CD4+ T cells purified from the KBN mice at the end of the treatment with Met+2DG,
2DG or control. Statistical analyses shown for the mean values of basal ECOR and ECAR (left of the graphs) and SRC or maximal ECAR (right of the graphs) between
the treated and control mice evaluated with t-tests. The first row indicates comparison between 2DG and control, and the second row between 2DG and controls.
**p < 0.01; ***p < 0.001.
DISCUSSION
To produce high levels of anti-GPI IgG, KBN arthritis strongly
relies on the expansion of CD4+ follicular helper T (Tfh) cells and
IL-21 they secrete, both which are required for the production of
high-affinity class-switched antibodies (22). Approximately 2/3
of RA patients (“seropositive patients”) produce class-switched
rheumatoid factor and/or anti-cyclic citrullinated peptide (CCP)
autoantibodies. The therapeutic efficacy of depleting B cells
with rituximab and blocking CD4+ T cell co-stimulation with
abatacept (CTLA4-Ig) strongly support a strong contribution
of B and T cells leading to the production of autoantibodies
to the pathogenesis of RA (23). Furthermore, a population
related to Tfh cells coined peripheral helper T cells (Tfp) is
expanded in the serum and the joints of seropositive RA patients
(24), supporting a critical role of such T cells in providing
help to autoantibody producing B cells in RA. Finally, the
expansion of a novel population of “Tfh-like” CXCR5+ Th17
cells correlates with disease activity in RA patients, and it is
refractory to TNF blockade (25). Tfh17 cells are also expanded
in KBN mice under the control of the microbiome (26). Recent
studies have shown that Th17 cells are dispensable for the
development of disease (27) and that the gut microbiome
regulates KBN Tfh but not Th17 cells (28). Moreover, the
analysis of K/BxN IL-21-VFP.IL-17A-GFP mice directly showed
a robust expansion of IL-21-producing CD4+ T cells but very
few IL-17-procuding CD4+ T cells (Roopenian, unpublished).
However, transfer of Bifidobacterium adolescentis, a bacterium
that drives human Th17 cell differentiation, exacerbated disease
in the same KBN model (29). Regardless of whether the
expansion of Th17 cells is pathogenic in the KBN model
or the result of a bystander effect, it corresponds to the
well-documented expansion of Th17 cells in RA patients
(30–35).
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FIGURE 7 | Differential effects of Met+2Dg and 2DG alone in vivo treatment on the expansion of immune subsets. Frequency of Tfh cells (A), CD4+ T cells
expressing the activation marker CD69 (B), IL-17A producing CD4+ T cells (C), Treg cells (B), Tem cells (E), GC B cells (F), and plasma cells (D) in the spleen.
Numbers of monocytes (H), neutrophils (I), pDCs (J), CD11b+ (K) and CD11− (L) in the DCs JDLN. There was not significant difference between males and females,
and their samples were pooled. Mean values between treated and control mice were evaluated with one-way ANAOVA and multiple comparison tests. *p < 0.05,
**p < 0.01; ***p < 0.001.
In this study, we showed that CD4+ T cells and, to a lesser
extent, B cells from KBN mice are highly metabolic, with high
levels of mTORC1 activation, as well as mTORC2 in CD4+ T
cells. Early continued treatment with an inhibitor of glycolysis
significantly decreased the severity of joint inflammation. A
modest therapeutic effect was also when mice with established
disease, most likely due to the rapid onset of this severe disorder.
The preventive efficacy of 2DG was associated with a decreased
frequency and numbers of cell subsets that have been associated
with disease in this model. We hypothesize that the enhanced
metabolism of B cells in the KBN model is secondary to their
stimulation by highly metabolic autoreactive CD4+ T cells, and
that 2DG affects these activated B cells indirectly through a
primary effect on Tfh cells. In spontaneous mouse models of
lupus, we have shown that the inhibition of glucose metabolism
selectively targets autoreactive Tfh cells (Choi et al. unpublished).
Moreover, mTORC1 activation has been linked to autoreactive
Tfh cell expansion by promoting the translation of Bcl6, the
master regulator of Tfh cell gene expression, in the lupus -
like Def6tr/trSwap70−/− DKO mouse model (36). Th17 cells are
known to be highly glycolytic (14), including in the context of
arthritis (13). We propose that KBN mice are another model
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in which autoreactive Tfh cells are highly glycolytic and that
their function can be limited by inhibiting glucose metabolism.
Icos signaling activates mTOR in Tfh cells, which in turn drives
glycolysis (37). A recently completed clinical trial showed that
blocking mTOR activation with rapamycin in lupus patients
reduced disease activity, including arthritis (38). These results,
combined with the results presented in this study with KBNmice
suggest that treatments with rapamycin may also be beneficial in
seropositive RA patients.
Although we only assessed a relative short-term treatment
with 2DG, joint inflammation was not reduced to pre-disease
status, therefore suggesting that some pathogenic effector
functions were glucose-independent. It is possible that the dosage
we used was insufficient. Arguing against this possibility is the
profound reduction of CD4+ T cell metabolism from KBN mice
treated with 2DG (Figure 6). A potential effect of metformin
was supported by the fact that as for CD4+ T cells from lupus
prone mice (3), both glycolysis and respiration were elevated
in KBN CD4+ T cells. Contrary to lupus mice however (3), we
did not observe an additional benefit from metformin in KBN
mice, arguing that glucose is dominant in their pathogenesis. This
result is consistent with highly glycolytic CD4+ T cells in human
RA (39) in an hyper-reduced state (9). This is in contrast with
lupus in which glycolysis plays an important role as evidenced
by the effect of 2DG [(3), Choi et al. unpublished], but there is
also evidence for a high level of oxidation in mice (8) and in
patients (40, 41). Metformin has been shown to have a protective
effect in collagen-induced arthritis (CIA), largely by preventing
the expansion of Th17 cells and expanding the Treg population
(42, 43). The effect of metformin on Tfh cells was not examined
in these studies. In the KBN model, we did not observe an
additional benefit of metformin over 2DG on the Th17 cells.
Ongoing experiments with KBN mice treated with metformin
alone should be informative whether the metabolic requirements
of effector CD4+ T cells differ between the CIA and KBN
models.
Metformin prevents the development of arthritis in the
KBN serum transfer model, indicating a major effect on the
innate immune effector cells (44). Interestingly, the addition of
metformin to the 2DG treatment renders the autoantibodies
produced by the KBN treated mice more pathogenic than those
produced by mice treated with 2DG alone. This qualitative
difference may due to their different ability to recruit innate
immune cells based on their expression of Fc receptors specific
to certain IgG isotypes. For instance, IgG1/GPI immune complex
would preferentially recruit innate cells expressing FcγRIII (45),
since in mice, IgG1 is the preferential ligand of FcγRIII, which
is expressed on both neutrophils and monocytes (46). Anti-GPI
IgG1 Abs are dominant in sera from KBN mice (16). However,
FcγRIV, a preferential receptor for IgG2 isotypes also expressed
on monocytes/macrophages and neutrophils, is required for
KBN serum-mediated inflammation (47). Since the addition of
metformin reduces the effect of 2DG on neutrophils, pDCs
and CD11b-negative DCs, future studies should address the
respective metabolic status of the innate subsets in the KBN
model, as well as the relative distribution of IgG1 and IgG2
anti-GPI isotypes.
Overall, this study showed that inhibition of glycolysis
significantly limits antibody-mediated pathology in the
KBN model of RA, most likely through its effect on
Tfh cells. The addition of metformin, which inhibits the
compensatory switch to the oxidation of other substrates,
limits the efficacy of glycolysis inhibition. Our results
also suggest that a high glycolytic demand may be shared
among Tfh cells in antibody-mediated autoimmune
diseases.
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